Pulmonary arterial hypertension (PAH) is a rare but serious condition that affects the blood vessels in the lungs and places increasing strain on the heart. It belongs to a broader group of disorders called pulmonary hypertension, but PAH is a distinct clinical subtype with specific causes, diagnostic criteria, and treatment pathways.
Although treatment options have improved significantly in recent years, PAH remains a progressive disease that can lead to right heart failure if not diagnosed and managed early.
This guide explains pulmonary arterial hypertension in depth, including symptoms, causes, pathophysiology, types, diagnostic process, treatment options, prognosis, and long-term management strategies.
What Is Pulmonary Arterial Hypertension (PAH)?
Pulmonary arterial hypertension is a condition characterized by abnormally high blood pressure in the small arteries of the lungs, known as pulmonary arterioles.
These arteries become:
Narrowed
Thickened
Stiffened
As a result, blood flow through the lungs becomes restricted, forcing the right side of the heart to work harder to pump blood through the lungs.
Normal vs PAH Blood Flow
In a healthy system:
Blood flows from the right heart → lungs
Oxygen is absorbed
Blood returns to the left heart
In PAH:
Pulmonary arteries resist blood flow
Pressure rises abnormally
The right ventricle becomes overloaded
Over time, this leads to right heart enlargement and eventual failure.
Hemodynamic Definition of PAH (Clinical Criteria)
Pulmonary arterial hypertension is defined using precise hemodynamic measurements obtained through right heart catheterization.
Diagnostic Criteria:
Mean pulmonary arterial pressure (mPAP) > 20 mmHg
Pulmonary arterial wedge pressure ≤ 15 mmHg
Pulmonary vascular resistance ≥ 2 Wood units
These measurements distinguish PAH from other forms of pulmonary hypertension.
How Pulmonary Arterial Hypertension Develops (Pathophysiology)
PAH is not just a pressure problem—it is a progressive vascular remodeling disease.
1. Endothelial Dysfunction
The inner lining of blood vessels becomes damaged, disrupting normal regulation of:
Vessel dilation
Blood flow
Clot prevention
2. Vasoconstriction
Blood vessels become overly constricted due to imbalance between:
Vasodilators (e.g., nitric oxide)
Vasoconstrictors (e.g., endothelin-1)
3. Smooth Muscle Proliferation
Cells in the vessel walls begin to multiply, thickening the artery walls.
4. Thrombosis Formation
Small blood clots may form, further narrowing vessels.
5. Right Ventricular Strain
The right side of the heart compensates by:
Enlarging (hypertrophy)
Increasing workload
Eventually, this compensation fails, leading to right heart failure.
Pulmonary Arterial Hypertension vs Pulmonary Hypertension
Pulmonary hypertension (PH) is an umbrella term that includes multiple conditions.
PH includes:
Left heart disease
Lung disease
Blood clots
PAH
PAH is specifically:
Group 1 pulmonary hypertension
Primary disease of pulmonary arterioles
Understanding this distinction is critical for diagnosis and treatment.
Types of Pulmonary Arterial Hypertension
PAH is not a single disease but a group of related conditions.
Unlike other forms, CTEPH may be surgically treatable.
Primary Pulmonary Hypertension (Historical Term)
“Primary pulmonary hypertension” is an older term that is now largely replaced by:
Idiopathic pulmonary arterial hypertension (IPAH)
Both terms refer to PAH without an identifiable cause.
Secondary Pulmonary Hypertension
Secondary pulmonary hypertension refers to PH caused by another condition.
Common causes include:
Left heart disease
Chronic lung disease
Sleep apnea
Blood clots
Secondary PH is treated by addressing the underlying cause.
Epidemiology of Pulmonary Arterial Hypertension
PAH is rare but serious.
Estimated prevalence: 15–50 cases per million people
More common in women than men
Typically diagnosed between ages 30–60
Idiopathic PAH is the most frequently diagnosed subtype
Pulmonary Arterial Hypertension Symptoms
Symptoms often develop gradually and worsen over time.
Early Symptoms
Shortness of breath during exertion
Fatigue
Dizziness
Reduced exercise tolerance
Progressive Symptoms
Chest pain
Palpitations
Swelling in legs or abdomen
Fainting (syncope)
Advanced Symptoms
Shortness of breath at rest
Bluish lips or skin (cyanosis)
Severe fatigue
Signs of right heart failure
Physical Examination Findings (Clinical Signs)
Doctors may detect:
Loud second heart sound (P2)
Jugular vein distension
Right ventricular heave
Peripheral edema
These signs suggest advanced disease.
Causes and Risk Factors of PAH
PAH has multiple causes depending on subtype.
Genetic Causes
BMPR2 mutation (most common)
Familial inheritance patterns
Autoimmune Diseases
Scleroderma
Lupus
Infectious Causes
HIV
Schistosomiasis (in endemic regions)
Cardiovascular Conditions
Congenital heart defects
Drug Exposure
Appetite suppressants
Certain stimulants
Diagnostic Process for PAH
Diagnosis requires multiple steps.
Step 1: Clinical Evaluation
Symptoms review
Physical examination
Step 2: Screening Tests
Echocardiogram (first-line tool)
Step 3: Confirmation
Right heart catheterization (gold standard)
Step 4: Classification
Determining WHO group
Identifying underlying cause
Step 5: Functional Testing
6-minute walk test
Exercise tolerance assessment
Differential Diagnosis
PAH must be differentiated from:
Asthma
COPD
Heart failure
Anxiety disorders
Misdiagnosis is common due to overlapping symptoms.
Risk Stratification in PAH
Doctors assess severity using:
Functional class (I–IV)
Exercise capacity
Biomarkers (e.g., BNP levels)
Imaging findings
This helps predict outcomes and guide treatment.
Pulmonary Arterial Hypertension Treatment
Treatment is aimed at:
Reducing symptoms
Slowing disease progression
Improving survival
1. First-Line Medications
Endothelin receptor antagonists
PDE-5 inhibitors
Soluble guanylate cyclase stimulators
2. Prostacyclin Therapy
IV or inhaled vasodilators
Used in more advanced cases
3. Combination Therapy
Many patients require multiple drugs for optimal control.
4. Surgical Options
Lung transplantation
Pulmonary endarterectomy (for CTEPH)
Atrial septostomy in select cases
Supportive Therapy for PAH
Supportive care improves quality of life.
Oxygen Therapy
Helps maintain oxygen levels and reduce strain on the heart.
Lifestyle Adjustments
Low-sodium diet
Fluid management
Avoiding strenuous activity
Pulmonary Rehabilitation
Supervised exercise
Breathing training
Physical conditioning
Psychological Support
Counseling
Support groups
Stress management
Complications of PAH
If untreated, PAH can lead to:
Right heart failure
Arrhythmias
Fluid overload
Reduced oxygen delivery
Death
Pulmonary Arterial Hypertension Prognosis
Prognosis depends on:
Type of PAH
Severity at diagnosis
Response to treatment
Functional class
Survival Trends
Early diagnosis improves survival
Modern therapies have significantly improved outcomes
Advanced PAH still carries serious risk
Living With Pulmonary Arterial Hypertension
Managing PAH requires lifelong care.
Daily Management
Medication adherence
Symptom tracking
Regular follow-ups
Activity Limitations
Avoid high-intensity exercise
Monitor oxygen levels
Travel Considerations
Avoid high altitudes
Plan medical support in advance
Pregnancy Risks
Pregnancy is high-risk and requires specialist supervision.
When to See a Doctor
Seek medical attention for:
Persistent shortness of breath
Chest pain
Fainting episodes
Swelling in legs or abdomen
When to Seek Emergency Care
Immediate care is needed for:
Severe breathlessness
Chest pain
Collapse or loss of consciousness
Prevention and Risk Reduction
While PAH cannot always be prevented, risk can be reduced by:
Managing autoimmune diseases
Avoiding harmful drugs
Early treatment of heart and lung conditions
Frequently Asked Questions (FAQs)
What is pulmonary arterial hypertension?
A condition where small lung arteries become narrowed, increasing pressure and straining the heart.
Is PAH curable?
No, but it is treatable and manageable with modern therapies.
What is the difference between PAH and PH?
PAH is a specific subtype of pulmonary hypertension affecting small pulmonary arteries.
What is idiopathic PAH?
PAH with no identifiable cause.
What is CTEPH?
A form of pulmonary hypertension caused by chronic blood clots in the lungs.
Conclusion
Pulmonary arterial hypertension is a complex, progressive, and potentially life-threatening condition. However, with early diagnosis, modern targeted therapies, and structured long-term care, patients can significantly improve both survival and quality of life.
Understanding its types, causes, diagnostic process, and treatment pathways is essential for effective management and better outcomes.